Conservative treatment of the uremic syndrome

Seminars in Dialysis

Volumn 22, Issue 4, 2009, Pages 449-453

  Vanholder, Raymond ^a   Argilés, Angel ^b   Beige, Joachim ^c   Brunet, Philippe ^d   Drüeke, Tilman B ^e   Fliser, Danilo ^f   Herget Rosenthal, Stefan ^g   Hörl, Walter H ^h   Jörres, Achim ⁱ   Perna, Alessandra ^j   Rodriguez Portillo, Mariano ^k   Spasovski, Goce ^l   Stegmayr, Bernd ^m   Stenvinkel, Peter ⁿ   Wanner, Christoph ^o   Wiecek, Andrzej ^p   Massy, Ziad A ^q  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b INSERM   (France)

^c Klinikum St Georg   (Germany)

^d AIX MARSEILLE UNIVERSITY   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f SAARLAND UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j Università degli Studi di Napoli BFederico II   (Italy)

^k HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^l University Clinical Center Skopje   (Macedonia)

^m UMEÅ UNIVERSITY HOSPITAL   (Sweden)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^p MEDICAL UNIVERSITY OF SILESIA   (Poland)

^q AMIENS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

URINARY TRACT AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; DIET; HUMAN; LIFESTYLE; UREMIA;

CARDIOVASCULAR DISEASES; DIET; HUMANS; LIFE STYLE; RENAL AGENTS; UREMIA;

EID: 69249148194     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2009.00600.x     Document Type: Article

References (42)

1. Vanholder R, De Deyn PP, Van Biesen W, Lameire N : Marconi revisited: from kidney to brain - two organ systems communicating at long distance. J Am Soc Nephrol 19 : 1253 1255, 2008
2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS : Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 : 1 12, 2003
3. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N : Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20 : 1048 1056, 2005
4. Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y : Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 70 : 794 799, 2006
5. Rashid H : Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren. Curr Med Res Opin 24 : 2627 2637, 2008
6. Jankowski V, Vanholder R, van der Giet M, Tolle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN, Tepel M, Schuchardt M, Schluter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, Jankowski J : Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 27 : 297 302, 2007
7. Sealey JE, Laragh JH : Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens 22 : 112 121, 2009
8. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R : Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41 : 1438 1444, 2003
9. Rodriguez M, Lorenzo V : Parathyroid hormone, a uremic toxin. Semin Dial 22 : 363 368, 2009
10. Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R : Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant, in press.
11. Dworkin LD, Feiner HD, Parker M, Tolbert E : Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 39 : 1112 1117, 1991
12. Carrero JJ, Park S-H, Axelsson J, Lindholm B, Stenvinkel P : Cytokines, atherogenesis and hypercatabolism in chronic kidney disease: a dreadful triad. Semin Dial 22 : 381 386, 2009
13. Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C : Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 74 : 1461 1467, 2008
14. Chertow GM, Burke SK, Raggi P : Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 : 245 252, 2002
15. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P : Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 : 1815 1824, 2005
16. Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfeld R, Ketteler M, Meert N, Maizel J, Nikolov IG, Vanholder R, Lacour B, Drueke TB, Massy ZA : Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 112 : 2875 2882, 2005 (Pubitemid 41641683)
17. Mathew S, Lund RJ, Strebeck F, Tustison KS, Geurs T, Hruska KA : Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 18 : 122 130, 2007
18. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M : A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51 : 952 965, 2008
19. Barreto DV, Barreto FC, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME : Phosphate binder impact on bone remodeling and coronary calcification - results from the BRiC study. Nephron Clin Pract 110 : c273 c283, 2008
20. Floege J : Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them? Nephrol Dial Transplant 23 : 3050 3052, 2008
21. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM : Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71 : 438 441, 2007
22. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK : Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72 : 1130 1137, 2007
23. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 : S1 S201, 2003
24. Foley RN, Parfrey PS, Sarnak MJ : Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 : S112 S119, 1998
25. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM : Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 : 1478 1483, 2000
26. Spasovski GB, Sikole A, Gelev S, Masin-Spasovska J, Freemont T, Webster I, Gill M, Jones C, De Broe ME, D'Haese PC : Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 21 : 2217 2224, 2006
27. Lacour B, Lucas A, Auchere D, Ruellan N, de Serre Patey NM, Drueke TB : Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 67 : 1062 1069, 2005
28. Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA : Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 110 : c15 c23, 2008
29. Kobayashi N, Maeda A, Horikoshi S, Shirato I, Tomino Y, Ise M : Effects of oral adsorbent AST-120 (Kremezin) on renal function and glomerular injury in early-stage renal failure of subtotal nephrectomized rats. Nephron 91 : 480 485, 2002
30. Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, Motojima M, Fukagawa M : Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant 21 : 2768 2774, 2006
31. Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N : A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 47 : 565 577, 2006
32. Konishi K, Nakano S, Tsuda S, Nakagawa A, Kigoshi T, Koya D : AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects. Diabetes Res Clin Pract 81 : 310 315, 2008
33. Koleganova N, Piecha G, Ritz E, Bekeredjian R, Schirmacher P, Schmitt CP, Gross ML : Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calcimimetic. Lab Invest, in press.
34. Koleganova N, Piecha G, Ritz E, Schmitt CP, Gross ML : A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 75 : 60 71, 2009
35. Ivanovski O, Nikolov IG, Joki N, Caudrillier A, Phan O, Mentaverri R, Maizel J, Hamada Y, Nguyen-Khoa T, Fukagawa M, Kamel S, Lacour B, Drueke TB, Massy ZA : The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE(-/-) mice. Atherosclerosis, in press.
36. Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriguez M : Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 17 : 795 804, 2006
37. Strippoli GF, Palmer S, Tong A, Elder G, Messa P, Craig JC : Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 47 : 715 726, 2006
38. Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, Mix TC, Kubo Y, Block GA : A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 53 : 197 207, 2009
39. Miyachi H : Design, synthesis, and structure-activity relationship study of peroxisome proliferator-activated receptor (PPAR) delta-selective ligands. Curr Med Chem 14 : 2335 2343, 2007 (Pubitemid 47618042)
40. Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E : Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 19 : 182 187, 2008
41. Yang HC, Ma LJ, Ma J, Fogo AB : Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 69 : 1756 1764, 2006
42. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chailhiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S : Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372 : 547 553, 2008